CN114903879B - 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 - Google Patents
3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 Download PDFInfo
- Publication number
- CN114903879B CN114903879B CN202210719518.5A CN202210719518A CN114903879B CN 114903879 B CN114903879 B CN 114903879B CN 202210719518 A CN202210719518 A CN 202210719518A CN 114903879 B CN114903879 B CN 114903879B
- Authority
- CN
- China
- Prior art keywords
- phenol
- ampk
- cells
- heptadecyltrialkenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 13
- 230000002265 prevention Effects 0.000 title claims description 3
- 208000030159 metabolic disease Diseases 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 title description 9
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims abstract description 30
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 22
- 239000000556 agonist Substances 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 18
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract description 10
- 208000008589 Obesity Diseases 0.000 abstract description 5
- 210000005229 liver cell Anatomy 0.000 abstract description 5
- 235000020824 obesity Nutrition 0.000 abstract description 5
- 108010028924 PPAR alpha Proteins 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 230000026731 phosphorylation Effects 0.000 abstract description 3
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 3
- 150000001335 aliphatic alkanes Chemical group 0.000 abstract description 2
- 150000001336 alkenes Chemical group 0.000 abstract description 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 32
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 32
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 32
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 32
- 239000005642 Oleic acid Substances 0.000 description 32
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 32
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 32
- 230000000694 effects Effects 0.000 description 22
- -1 Z-heptadecdienyl Chemical group 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 150000002632 lipids Chemical class 0.000 description 18
- 229940125904 compound 1 Drugs 0.000 description 15
- 229940125782 compound 2 Drugs 0.000 description 15
- 150000003626 triacylglycerols Chemical class 0.000 description 15
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 235000009200 high fat diet Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 8
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 6
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 239000002024 ethyl acetate extract Substances 0.000 description 6
- 230000037356 lipid metabolism Effects 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 5
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 235000006647 Eugenia jambos Nutrition 0.000 description 4
- 244000087016 Syzygium jambos Species 0.000 description 4
- 238000010306 acid treatment Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- PEUHBSAKNWEJHZ-UHFFFAOYSA-N heptadeca-1,3-diene Chemical compound CCCCCCCCCCCCCC=CC=C PEUHBSAKNWEJHZ-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102000049320 CD36 Human genes 0.000 description 3
- 108010045374 CD36 Antigens Proteins 0.000 description 3
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 3
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 3
- 101000833892 Homo sapiens Peroxisomal acyl-coenzyme A oxidase 1 Proteins 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100026798 Peroxisomal acyl-coenzyme A oxidase 1 Human genes 0.000 description 3
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000006372 lipid accumulation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000003614 peroxisome proliferator Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- PEUHBSAKNWEJHZ-ALCCZGGFSA-N (3Z)-heptadeca-1,3-diene Chemical compound CCCCCCCCCCCCC\C=C/C=C PEUHBSAKNWEJHZ-ALCCZGGFSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101710103514 Acyl-coenzyme A oxidase 1 Proteins 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100108090 Caenorhabditis elegans acox-1.1 gene Proteins 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102100031574 Platelet glycoprotein 4 Human genes 0.000 description 1
- 101710202087 Platelet glycoprotein 4 Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 244000045719 Syzygium Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101000833887 Yarrowia lipolytica (strain CLIB 122 / E 150) Acyl-coenzyme A oxidase 1 Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000021250 regulation of fatty acid beta-oxidation Effects 0.000 description 1
- 230000009627 regulation of fatty acid transport Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/004—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by obtaining phenols from plant material or from animal material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了3‑烃基苯酚衍生物在制备预防或治疗高血脂症及相关代谢性疾病产品中的用途,属于生物医药领域。所述3‑烃基苯酚类化合物的结构通式为式I所示:。其中,R为含有9~26个碳的烷烃或烯烃侧链;R上的双键选自0~3个。本发明所述3‑烃基苯酚衍生物可激活肝脏细胞AMPK和PPARα信号通路,促进AMPK的α亚基Thr172位点的磷酸化,增强PPARα的转录活性,可用来制备AMPK或PPARα激动剂,也可用于制备预防或治疗高脂血症、糖尿病、肥胖、非酒精性脂肪性肝病、高血压、动脉粥样硬化及其并发症的药物。
Description
技术领域
本发明属于生物医药领域,具体涉及3-烃基苯酚衍生物在制备AMPK或PPARα激动剂中的用途,另外还涉及3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途。
背景技术
脂质是人体中一类重要的生物有机分子,包括脂肪酸(FA)、胆固醇(TC)、甘油三酯(TG)以及磷脂、糖脂等类脂成分,在维持机体正常生命活动方面发挥重要作用。脂质代谢是一个复杂过程,包括TG的合成及转运、脂肪酸的合成及β氧化分解以及胆固醇的代谢等。机体脂质代谢网络复杂,受肝脏、肠道、脂肪等多种组织器官调控。当人体内能量的摄入与消耗、合成与分解代谢长期处于不平衡状态时,将导致脂质代谢紊乱。临床上常见的高脂血症,其特点是患者血液中甘油三酯和/或低密度脂蛋白水平升高,部分出现高密度脂蛋白水平降低。高脂血症可引发多种慢性代谢性疾病,例如2型糖尿病、肥胖、非酒精性脂肪性肝病、心血管系统疾病等,严重威胁人类健康。发现安全性高、降血脂效果显著的新型药物或保健品具有重要的实际应用价值。
腺苷酸活化蛋白激酶(adenosine monophosphate-activated protein kinase,AMPK)是由催化的α亚基和调节的β、γ亚基构成的异源三聚体,是细胞能量状态的关键感受器,在人体的肝脏等多种脏器组织细胞中均有较高表达。作为一种重要的蛋白激酶,AMPK在机体脂质代谢过程中发挥重要作用。在细胞能量缺乏状态下,AMPK可通过其α亚基Thr172的磷酸化而激活,进而抑制细胞中的合成代谢并促进分解代谢来维持脂质代谢的平衡。肝脏中的AMPK通过直接磷酸化固醇调节元件结合蛋白1(sterol-regulatory element bindingprotein 1,SREBP1)的Ser372位点,抑制其转录,进而下调SREBP1下游脂肪酸合酶(fattyacid synthase,FAS)的表达,从而减少脂肪酸的从头合成。鉴于AMPK在能量代谢中的重要作用,其已成为防治代谢性疾病如肥胖症、糖尿病、非酒精性脂肪性肝病等的重要药物靶点。
过氧化物酶体増殖物激活受体α(peroxisome proliferators-activatedreceptor alpha,PPARα)属核受体家族中配体激活的转录因子,主要分布在线粒体脂肪酸氧化效率髙的组织,如肝脏、心脏、肾脏、肠等。大量证据表明,PPARα是肝脏脂质代谢调节的重要参与者,参与调控脂肪酸转运和β氧化、甘油三酯和脂滴的形成和分解以及血浆脂蛋白代谢等。PPARα可以被内源性脂肪酸及其代谢产物等天然配体激活,而一些临床上使用的部分降血脂药物如贝特类也属于PPARα激动剂。PPARα经配体激活后,与维甲酸X受体(retinoid X receptor,RXR)形成异二聚体,结合到靶基因启动子区域过氧化物酶体增殖物反应元件(peroxisome proliferator response element,PPRE)上,通过DNA结合依赖途径调控下游靶基因的转录9。在脂肪酸代谢过程中,参与脂肪酸摄取与转运的的一些蛋白如脂肪酸转位酶36(cluster of differentiation 36,CD36),以及脂肪酸β氧化的关键酶如肉毒碱棕榈酰转移酶1(carnitine palmitoyltransferase 1,CPT1)、酰基辅酶A氧化酶1(Acyl-Coenzyme A oxidase 1,ACOX1)和羟烷基辅酶A脱氢酶(hydroxyacyl-Coenzyme Adehydrogenase,HADHA)均受PPARα调控。PPARα激动剂在高血脂、肥胖、心血管疾病等药物研发中具有广阔的应用前景。
3-烃基苯酚是酚类脂质,其结构特点为苯酚的3位连接不同长度的烃基侧链,并且部分结构在侧链上有1或多个不饱和双键。天然来源的3-烃基苯酚类成分在腰果壳、银杏以及蒲桃属植物中含量丰富,被报道具有抗菌、抗氧化、抗突变以及抗肿瘤等活性,然而关于该类成分对AMPK和PPARα的调节作用尚无相关报道。肝脏是机体脂质代谢重要器官,因此研究3-烃基苯酚类成分对肝脏细胞AMPK和PPARα的调节作用将为揭示该类成分的生物学功能奠定实验基础,对于推动其在预防或治疗高脂血症及相关代谢性疾病的药物中的应用具有积极意义。
发明内容
本发明的目的在于提供3-烃基苯酚衍生物在制备AMPK或PPARα激动剂中的用途,本发明的目的还在于提供3-烃基苯酚衍生物在预防或治疗高脂血症及相关代谢性疾病产品中的用途。
具体地,通过以下几个方面的技术方案实现了本发明:
在第一个方面中,本发明提供了一种具有激动AMPK或PPARα信号通路作用的3-烃基苯酚衍生物,其结构通式为式I所示化合物:
其中,R为含有9~26个碳的烷烃或烯烃侧链。
作为可选的方式,在上述3-烃基苯酚衍生物中,R为C9-C26直链烃基,R上的双键选自0~3个。
作为可选的方式,在上述3-烃基苯酚衍生物中,R为C12-C20直链烃基,R上的双键为2个或3个。
作为可选的方式,在上述3-烃基苯酚衍生物中,所述式I化合物选自以下:
3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚或3-(8'Z,11'Z-十七烷二烯基)-苯酚。
在第二个方面中,本发明提供了上述第一个方面所述的3-烃基苯酚衍生物的制备方法,所述制备方法包括以下步骤:
选用新鲜蒲桃果实,切片后脱水干燥,干燥的蒲桃果实薄片直接用90%乙醇室温提取3次,提取液过滤后减压浓缩干燥得乙醇提取物,乙醇提取物用水溶解后,采用乙酸乙酯萃取,乙酸乙酯萃取液减压浓缩干燥得乙酸乙酯提取物,乙酸乙酯提取物经小孔树脂柱层析,采用甲醇/水梯度洗脱,分别得到100%水洗脱组分、20%甲醇洗脱组分、40%甲醇洗脱组分、60%甲醇洗脱组分、80%甲醇洗脱组分以及100%甲醇洗脱组分,其中100%甲醇洗脱组分经Sephadex LH-20凝胶柱层析,100%甲醇洗脱,经TLC显色合并相似组分,最后经反相ODS柱色谱进一步纯化,得到所述3-烃基苯酚衍生物样品。
作为可选的方式,在上述制备方法中,所述反相ODS柱色谱的洗脱条件为甲醇/水梯度洗脱,80%甲醇→90%甲醇→100%甲醇。
在第三个方面中,本发明提供了上述第一个方面所述的3-烃基苯酚衍生物或者采用上述第二个方面所述的制备方法制备得到的3-烃基苯酚衍生物在制备AMPK或PPARα激动剂中的用途。
作为可选的方式,在上述用途中,所述AMPK或PPARα激动剂可以用于制备药物、体内或体外科学研究工具药或者诊断试剂。
在第四个方面中,本发明提供了上述第一个方面所述的3-烃基苯酚衍生物或者采用上述第二个方面所述的制备方法制备得到的3-烃基苯酚衍生物在制备预防或治疗高脂血症或相关代谢性疾病产品中的用途。
作为可选的方式,在上述用途中,所述相关代谢性疾病选自以下:糖尿病、肥胖或非酒精性脂肪性肝病。
作为可选的方式,在上述用途中,所述产品选自药物。
作为可选的方式,在上述用途中,所述产品中还包含药物领域可接受的载体和/或赋形剂。
本发明相对于现有技术,具有以下有益效果:
(1)本发明提供了式I所示化合物及其在制备AMPK和/或PPARα激动剂产品中的用途。另外,本发明提供了式I所示的化合物及其在制备预防和治疗高脂血症及其相关代谢性疾病产品中的用途。
(2)实验结果表明,式I所示的3-烃基苯酚衍生物可显著降低油酸处理的HepG2细胞甘油三酯水平,改善肝脏细胞脂质代谢紊乱,可激活肝脏细胞AMPK及PPARα信号通路,促进AMPK的α亚基Thr172的磷酸化,增强PPARα的转录活性,改善肝脏细胞脂质代谢紊乱,可改善高脂肪饮食导致的小鼠肝脏脂质异常沉积,缓解小鼠非酒精性脂肪性肝病的病理状态。
附图说明
图1:油酸处理对HepG2细胞甘油三酯(TG)含量的影响。
图2:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯基)-苯酚对油酸诱导HepG2细胞存活率的影响。
图3:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(图3A)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(图3B)对油酸诱导HepG2细胞TG含量的影响。
图4:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯基)-苯酚对油酸诱导HepG2细胞脂滴聚集的影响。
图5:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯基)-苯酚对油酸诱导HepG2细胞中AMPK信号通路中p-AMPK,FAS,SREBP-1蛋白表达的影响。
图6:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚对si-AMPK干预后油酸诱导HepG2细胞中AMPK信号通路相关蛋白表达的影响。
图7:3-(8'Z,11'Z-十七烷二烯)-苯酚对si-AMPK干预后油酸诱导HepG2细胞中AMPK信号通路相关蛋白表达的影响。
图8:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯)-苯酚对油酸诱导HepG2细胞中PPARα及其下游靶基因表达的影响。
图9:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯)-苯酚对PPARα转录激活活性的影响。
具体实施方式
下面参照具体的实施例对本发明做进一步说明。应当理解,此处所描述的具体实施例仅用于解释本发明,并不用于限定本发明的范围。
实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道购买得到的常规产品。
下面实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的试验材料,如无特殊说明,均为市售产品。
制备实施例:下述实施例中的3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚以及3-(8'Z,11'Z-十七烷二烯基)-苯酚由以下方法制备:
选用新鲜蒲桃果实,切片后脱水干燥。干燥的蒲桃果实薄片直接用90%乙醇室温提取3次(料液比1:10),每次24小时。提取液过滤后40℃减压浓缩干燥得乙醇提取物。乙醇提取物用水溶解后,采用乙酸乙酯萃取。乙酸乙酯萃取液40℃减压浓缩干燥得乙酸乙酯提取物。乙酸乙酯提取物经MCI CHP-20P小孔树脂柱层析,采用甲醇/水梯度洗脱,分别得到100%水洗脱组分、20%甲醇洗脱组分、40%甲醇洗脱组分、60%甲醇洗脱组分、80%甲醇洗脱组分以及100%甲醇洗脱组分。其中100%甲醇洗脱组分经Sephadex LH-20凝胶柱层析,100%甲醇洗脱,经TLC显色合并相似组分,最后经反相ODS柱色谱(甲醇/水梯度洗脱,80%甲醇→90%甲醇→100%甲醇)进一步纯化,得到3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯)-苯酚样品。其化合物结构式如下,1H-和13C-NMR确定化合物结构。
3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚
3-(8'Z,11'Z-十七烷二烯基)-苯酚
效果实施例:实施例1:建立油酸诱导脂质累积HepG2细胞模型
1. 油酸配置:15 μL油酸溶于100 μL无水乙醇中,混合均匀,然后将此混合液加入到5 mL 10%牛血清白蛋白(BSA)中充分溶解,得到10 mM油酸母液。4 ℃保存备用。使用前用无血清DMEM培养基稀释至终浓度200µM。
2. 细胞处理:取对数生长期HepG2细胞,按1×105细胞/孔接种于6孔板。待细胞贴壁生长后,使用含终浓度200µM油酸的无血清DMEM培养基继续培养24 h。
3. 细胞中甘油三酯(TG)含量测定:弃去培养基,使用细胞裂解液(RIPA裂解液:磷酸酶抑制剂:蛋白酶抑制剂=100:1:1)冰上裂解细胞。取部分裂解后样本,选择南京建成甘油三酯测定试剂盒,按照试剂盒操作说明书测定细胞中TG含量。实验重复三次,取三次数值的平均值作为最终的TG含量。
4.结果如图1所示,与未加油酸处理的HepG2细胞相比,200µM油酸处理HepG2细胞,其TG含量增加了8.2倍,表明油酸诱导脂质累积HepG2细胞模型建立成功。
实施例2:MTT法考察3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯基)-苯酚对HepG2细胞增殖的影响
1. 药物配置:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯)-苯酚(化合物2)用DMSO溶解,分别配置成100 mM母液,4 ℃保存。使用前用无血清DMEM培养基稀释,使化合物终浓度分别为10、20、40、60以及80 µM;或者用含200µM油酸的无血清DMEM培养基稀释,使化合物终浓度分别为10、20、40、60以及80 µM。DMSO浓度小于1%。
2. 药物处理:取对数生长期HepG2细胞,按8×103细胞/孔接种于96孔板,CO2细胞培养箱孵育过夜。弃去旧培养基,空白组(CON组)更换为无血清DMEM培养基(100 µL);药物处理组细胞换用含不同浓度药物(10、20、40、60、80 µM)的无血清DMEM培养基(100 µL);油酸对照组(OA组)换用含200µM油酸的无血清DMEM培养;药物+油酸处理组细胞换用含有200µM油酸以及不同浓度药物(10、20、40、60、80 µM)的无血清DMEM培养基(100 µL)。培养24 h之后,每孔加入20 μL浓度为5 mg/mL的MTT溶液,在培养箱中继续孵育4 h。弃去上清,每孔加入150 μL的DMSO,室温条件下置于水平摇床10 min充分溶解。用酶标仪在波长490 nm处检测吸光值。实验独立重复三次。
3. 结果如图2所示,3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯)-苯酚(化合物2)在10-40 µM的浓度范围内对油酸诱导的HepG2细胞增殖无显著性影响。
实施例3:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯基)-苯酚对油酸处理HepG2细胞中甘油三酯含量的影响
1. 药物处理:取对数生长期HepG2细胞,按1×105细胞/孔接种于6孔板。待细胞贴壁生长后,使用含有200µM油酸以及不同浓度3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯)-苯酚(化合物2)(终浓度分别为10、20和40 μM)的无血清DMEM培养基继续培养24 h。罗格列酮为阳性药。
2. HepG2细胞中甘油三酯含量测定:按照实施例1中步骤3进行。实验重复三次,取三次数值的平均值作为最终的TG含量。
3. 结果如图3所示,相比于CON组,OA组细胞内TG含量显著升高。与OA组相比,3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)可显著降低细胞内的TG含量,且在所测定浓度下呈现剂量依赖性。3-(8'Z,11'Z-十七烷二烯基)-苯酚在40 μM浓度时降低TG的效果优于阳性药罗格列酮(100 μM)。
实施例4:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯基)-苯酚对油酸处理HepG2细胞中脂滴聚集的影响
1. 细胞培养:12孔板底部加入100 μL DMEM培养基,然后将0.14 mm专用圆片吸附在12孔板底部。调整细胞悬液浓度为5×104细胞/孔,每孔加入1 mL细胞悬液,恒温培养箱中继续培养24 h。
2. 药物处理:向孔中分别加入含有200µM油酸以及不同浓度3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)(终浓度分别为10、20和40 μM)的无血清DMEM培养基,恒温培养箱中继续培养。罗格列酮为阳性对照(终浓度为100 μM)。
3. 油红O染色:药物处理24 h后,弃去培养基并用PBS缓冲液洗涤细胞,后每孔加入4%多聚甲醛溶液室温固定30 min。之后每孔加入60%异丙醇溶液室温孵育5 min。弃去异丙醇溶液,每孔加入1 mL油红O工作液室温孵育20 min。PBS漂洗后用苏木素染液复染,甘油明胶封片。显微镜下观察细胞内部脂滴积累情况。
4. 结果如图4所示,未经油酸处理的CON组细胞边缘清晰、状态良好,脂滴数目少且无明显聚集现象。与CON组相比,OA组细胞内沉积了大量的红色脂滴,并存在脂滴融合现象。与OA组相比,3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)处理后细胞中红色脂滴的大小和数量均有所降低,说明3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)可以有效地改善油酸诱导的HepG2细胞内脂质积累。
实施例5:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯基)-苯酚对HepG2细胞AMPK及下游靶蛋白表达的影响
1. 药物处理:同实施例3中的步骤1。
2.Western blot实验:使用裂解液(细胞裂解液:蛋白酶抑制剂:磷酸酶抑制剂=100:1:1)裂解细胞,100 ℃金属浴10 min使蛋白样品变性。利用BCA法测定蛋白浓度,利用SDS-PAGE凝胶电泳进行蛋白分离,GAPDH为内参。电泳结束后,将蛋白转至PVDF膜,5%脱脂牛奶封闭1 h。之后在目标蛋白相应的一抗溶液中4 °C分别孵育过夜,然后在目标蛋白对应的二抗中室温孵育1 h。利用ECL发光液显影,通过凝胶图像分析系统获得目标条带。AMPK、p-AMPK、FAS、SREBP-1抗体均购置于Cell Sigaling Technology。
3. siRNA转染实验:取对数生长期HepG2细胞,按1×105细胞/孔接种于6孔板,培养过夜。待细胞贴壁生长后,利用Rfect转染试剂将siRNA-AMPK转染细胞,敲低AMPK在HepG2细胞中的表达,siRNA-CON作为对照组。将转染siRNA-AMPK的细胞进一步分为OA组和给药组。给药组分别给予3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)(终浓度40 μM)处理,OA组和给药组血清中均添加OA(终浓度200 μM),5% CO2恒温培养箱中继续孵育24 h。按步骤2进行Western blot实验,检测AMPK、FAS、SREBP-1蛋白表达情况。
4. 结果如图5所示,HepG2细胞经油酸处理后,p-AMPK表达水平显著降低。而3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)可显著逆转油酸诱导的HepG2细胞p-AMPK蛋白表达水平的降低,使之恢复正常水平且其作用呈剂量依赖性。此外,3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)干预降低了油酸处理HepG2细胞中FAS和SREBP-1等两个AMPK下游与脂质合成相关蛋白的表达。而利用siRNA转染敲低AMPK在HepG2细胞中的表达后,如附图6和7所述,3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)下调细胞中SREBP-1和FAS表达的作用显著降低。因此3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)可作为AMPK激动剂调控AMPK的激活及其下游蛋白的表达而发挥作用。
实施例6:3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯基)-苯酚对HepG2细胞PPARα激活的影响
1. 药物处理:同实施例3中的步骤1。PPARα激动剂WY14643作为阳性对照。
2. 总RNA提取:利用Trizol试剂在冰上裂解细胞,在裂解液中加入氯仿(VTrizol:V氯仿=5:1)后离心,吸取上清,加入等体积预冷的异丙醇,混合均匀并离心。弃去上清,75%乙醇洗涤沉淀,室温下晾干,即得总RNA。
3. 逆转录合成cDNA:根据反转录试剂盒操作说明书合成单链cDNA。按照RNA(1 μL)、Primer Mix(2 μL)、dNTP Mix(4 μL)、DTT(2 μL)、RT Buffer(4 μL)、HiFiScript(1 μL)和RNase-Free Water(6 μL)配置反应体系,总体积为20 μL。在PCR仪中42 ℃反应15 min,85 ℃孵育5 min,即得cDNA。
4. Real time- PCR:以合成的cDNA为模板,利用上下游引物扩增目的基因片段。PCR反应体系如下:UltraSYBR Mixture (High Rox)(5 μL),forward primer(1 μL),reverse primer(1 μL),cDNA(0.125 μL),ddH2O(2.875 μL),总体积为10 μL。反应程序:95°C预变性10 min;然后95°C,10 s;60°C,20 s;72°C,20 s,循环数44。以2-DDCt表示实验组目的基因的表达相对于对照组目的基因表达的倍数。PPARα、ACOX1、CPT1A、CD36、HADHA以及管家基因β-actin的引物序列见表1。
5. 结果如图8所示,OA组PPARα及其下游靶基因ACOX1、CPT1A、CD36、HADHA的表达水平显著低于CON组。与OA组相比,3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)能显著升高OA处理的HepG2细胞中PPARα、 ACOX1、CPT1A、CD36、HADHA等基因的表达水平,且呈现出剂量依赖性(10-40 μM)。
6. PPRE双荧光酶素报告实验:取对数生长期HepG2细胞,按3×105细胞/孔接种于6孔板。培养过夜,按照说明书利用转染试剂Lipo 3000将PPRE荧光素酶基因报告质粒PPRE-Luc转染到HepG2细胞。转染48 h后,分别加入40 μM的3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)处理细胞8 h。利用Promega双荧光素酶报告分析试剂盒和酶标仪检测细胞中荧光强度,计算荧光素酶活性。
7. 结果如图9所示,转染PPRE-Luc质粒后,与CON组相比,3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚(化合物1)和3-(8'Z,11'Z-十七烷二烯基)-苯酚(化合物2)处理显著增强了HepG2细胞中的荧光素酶活性,表明3-(8'Z,11'Z,14'Z-十七烷三烯基)-苯酚和3-(8'Z,11'Z-十七烷二烯基)-苯酚可作为PPARα的激动剂,增强PPARα对其下游靶基因的转录。
实施例7:3-(8'Z,11'Z-十七烷二烯基)-苯酚改善高脂饮食诱导非酒精性脂肪肝小鼠肝脏脂质异常沉积
1. 动物造模及给药:4周龄C57BL/6小鼠饲养于恒温恒湿的标准动物房中,自由饮水和进食。适应环境饲养一周后,将小鼠随机分为3组,每组8只。标准饮食组(SD)给予基础饲料,高脂饮食组(HFD)给予60% Kcal高脂饲料,高脂饮食+3-(8'Z,11'Z-十七烷二烯基)-苯酚组(HFD+P)饲喂高脂饲料并每天灌胃给药一次(250 mg/kg/d),SD组和HFD组灌胃同等体积的蒸馏水。持续干预11周。之后小鼠用异氟烷麻醉状态下处死,取小鼠肝脏组织。
2. 肝脏组织油红O染色:非酒精性脂肪肝的重要病理特征是肝脏脂质异常沉积。通过肝脏组织油红O染色考察3-(8'Z,11'Z-十七烷二烯基)-苯酚对非酒精性脂肪肝小鼠肝脏脂质异常沉积的改善作用。取适宜的小鼠肝脏组织,OCT包埋后冰冻切片,厚度为8 mm。将切片放入4%多聚甲醛中固定,用蒸馏水以及60%异丙醇漂洗。之后将固定好的切片放入油红O工作液中进行染色。染色结束后利用60%异丙醇使背景分化至无色;后将切片放入苏木素中染色,流水反蓝;最后用甘油明胶封片,显微镜下观察。
3. 肝脏组织H/E染色:高脂饮食会引起肝脏脂质异常蓄积,出现非酒精性脂肪肝样病变。肝脏中蓄积的油脂被二甲苯溶解后,出现大量空泡,并出现炎症浸润现象。通过H/E染色后组织病理学观察考察3-(8'Z,11'Z-十七烷二烯基)-苯酚对非酒精性脂肪肝小鼠肝脏脂质异常沉积的改善作用。肝脏组织切块,大小为10 mm×10 mm×2 mm,放入4%的多聚甲醛中固定。然后使用不同浓度梯度的乙醇依次进行脱水,脱水步骤为70%乙醇→80%乙醇→90%乙醇→95%乙醇→100%乙醇。然后将组织放入二甲苯中,透明。之后将组织块放入软蜡和硬蜡中进行包埋,再用石蜡切片机把包埋的肝脏组织块切片,厚度5 μm。将石蜡切片依次放入二甲苯和不同浓度的乙醇(100%乙醇→95%乙醇→90%乙醇→80%乙醇→70%乙醇)中进行脱蜡处理,然后利用苏木素染液进行染色。染色结束后,将石蜡切片放入1%盐酸酒精中分化,然后再利用伊红原液染色。结束后,将石蜡切片依次利用95%和100%乙醇脱水,二甲苯透明。最后用中性树胶封片,显微镜下观察。
4. 实验结果表明,3-(8'Z,11'Z-十七烷二烯基)-苯酚可改善高脂肪饮食导致的小鼠肝脏脂质异常沉积,缓解小鼠非酒精性脂肪性肝病的病理状态。
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。
Claims (1)
1.3-烃基苯酚衍生物在制备预防或治疗高脂血症的药物中的用途,其特征在于:所述3-烃基苯酚衍生物的结构为:,所述3-烃基苯酚衍生物是AMPK或PPARα激动剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210719518.5A CN114903879B (zh) | 2022-06-23 | 2022-06-23 | 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210719518.5A CN114903879B (zh) | 2022-06-23 | 2022-06-23 | 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114903879A CN114903879A (zh) | 2022-08-16 |
CN114903879B true CN114903879B (zh) | 2023-10-31 |
Family
ID=82772139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210719518.5A Active CN114903879B (zh) | 2022-06-23 | 2022-06-23 | 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114903879B (zh) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4499010A (en) * | 1980-09-19 | 1985-02-12 | Toyama Prefecture | Conductive paint |
JP2004196788A (ja) * | 2002-12-04 | 2004-07-15 | Kissei Pharmaceut Co Ltd | ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途 |
GB0517572D0 (en) * | 2005-08-27 | 2005-10-05 | Tyman John H P | Synthesis of 5-alkylresorcinols and 5-alkenyl resorcinols from aromatic aldehyde ozonolysis products obtained from resorcinolic natural and semi-synthetic |
CN101911938A (zh) * | 2010-07-29 | 2010-12-15 | 江苏大学 | 银杏酚酸类化合物在杀灭福寿螺上的用途 |
CN102639518A (zh) * | 2009-09-30 | 2012-08-15 | 株式会社富士药品 | 新型苯酚衍生物 |
CN103396438A (zh) * | 2013-08-16 | 2013-11-20 | 山东海力化工股份有限公司 | 亚磷酸三脂肪烃基苯酚酯的制备方法 |
WO2015099392A1 (ko) * | 2013-12-24 | 2015-07-02 | (주)이룸바이오테크놀러지 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
CN106916133A (zh) * | 2017-01-18 | 2017-07-04 | 东北大学 | 一种具有抑制ptp1b活性的间苯三酚衍生物及其制备方法、应用 |
JP2019104755A (ja) * | 2019-03-11 | 2019-06-27 | 国立研究開発法人産業技術総合研究所 | 抗肥満用食品及び飼料の給餌方法 |
CN110638798A (zh) * | 2019-10-16 | 2020-01-03 | 北京工商大学 | 烷基间苯二酚在制备用于预防或治疗肥胖症相关疾病产品中的应用 |
CN111888345A (zh) * | 2020-09-04 | 2020-11-06 | 北京工商大学 | 烷基间苯二酚在抗动脉粥样硬化中的应用 |
CN112933077A (zh) * | 2021-02-08 | 2021-06-11 | 东北大学 | 间苯三酚衍生物在制备用于治疗和/或预防癌症的药物中的用途 |
CN113768907A (zh) * | 2021-10-29 | 2021-12-10 | 北京工商大学 | 十七烷基间苯二酚在制备改善肌肉运动功能障碍产品中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9248145B2 (en) * | 2010-03-10 | 2016-02-02 | The United States Of America, As Represented By The Secretary Of Agriculture | Two alkylresorcinol synthase genes from sorghum; cloning, expression, transformation and characterization |
WO2015193962A1 (ja) * | 2014-06-17 | 2015-12-23 | 独立行政法人産業技術総合研究所 | 耐糖能異常改善剤 |
-
2022
- 2022-06-23 CN CN202210719518.5A patent/CN114903879B/zh active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4499010A (en) * | 1980-09-19 | 1985-02-12 | Toyama Prefecture | Conductive paint |
JP2004196788A (ja) * | 2002-12-04 | 2004-07-15 | Kissei Pharmaceut Co Ltd | ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途 |
GB0517572D0 (en) * | 2005-08-27 | 2005-10-05 | Tyman John H P | Synthesis of 5-alkylresorcinols and 5-alkenyl resorcinols from aromatic aldehyde ozonolysis products obtained from resorcinolic natural and semi-synthetic |
CN102639518A (zh) * | 2009-09-30 | 2012-08-15 | 株式会社富士药品 | 新型苯酚衍生物 |
CN101911938A (zh) * | 2010-07-29 | 2010-12-15 | 江苏大学 | 银杏酚酸类化合物在杀灭福寿螺上的用途 |
CN103396438A (zh) * | 2013-08-16 | 2013-11-20 | 山东海力化工股份有限公司 | 亚磷酸三脂肪烃基苯酚酯的制备方法 |
WO2015099392A1 (ko) * | 2013-12-24 | 2015-07-02 | (주)이룸바이오테크놀러지 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
CN106916133A (zh) * | 2017-01-18 | 2017-07-04 | 东北大学 | 一种具有抑制ptp1b活性的间苯三酚衍生物及其制备方法、应用 |
JP2019104755A (ja) * | 2019-03-11 | 2019-06-27 | 国立研究開発法人産業技術総合研究所 | 抗肥満用食品及び飼料の給餌方法 |
CN110638798A (zh) * | 2019-10-16 | 2020-01-03 | 北京工商大学 | 烷基间苯二酚在制备用于预防或治疗肥胖症相关疾病产品中的应用 |
CN111888345A (zh) * | 2020-09-04 | 2020-11-06 | 北京工商大学 | 烷基间苯二酚在抗动脉粥样硬化中的应用 |
CN112933077A (zh) * | 2021-02-08 | 2021-06-11 | 东北大学 | 间苯三酚衍生物在制备用于治疗和/或预防癌症的药物中的用途 |
CN113768907A (zh) * | 2021-10-29 | 2021-12-10 | 北京工商大学 | 十七烷基间苯二酚在制备改善肌肉运动功能障碍产品中的应用 |
Non-Patent Citations (8)
Title |
---|
5-二十一烷基间苯二酚抑制α-葡萄糖苷酶活性的分子机制;屠洁;刘冠卉;朱淑云;曹喜涛;李强;季更生;;食品科学(第19期);第122-127页 * |
Discovery, preparation and characterization of lipid-lowering alkylphenol derivatives from Syzygium jambos fruit;Wen Xu,等;Food Chem;第1-12页 * |
J.A.Lamberton.STUDIES OF THE OPTICALLY ACTIVE COMPOUNDS OF AFACARDIACEAE EXUDATES.1958,第234-239页. * |
New antimicrobial terpenoids and phloroglucinol glucosides from Syzygium szemaoense;Xu W,等;Bioorg Chem;1-10 * |
Repurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identification of potential SARSCOV-2 inhibitors;Boadu A,等;Sci Rep;第12卷(第1期);1-14 * |
小麦麸皮的营养特性与应用进展;吴凡;蔡红燕;沈汪洋;党长英;孙云杰;;食品工业(第05期);第289-292页 * |
烃基酚类化合物对四膜虫毒性的定量结构-活性相关研究;王晓丽,等;分析化学;第37卷(第06期);817-822 * |
谷物纤维摄入量与妊娠期糖尿病的关联研究;李秀梅;;中外医疗(第22期);第7-10+24页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114903879A (zh) | 2022-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yamada et al. | Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice | |
Duval et al. | Niemann–Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine | |
JP5728726B2 (ja) | トマト抽出物を含有する生活習慣病改善剤 | |
CN101072509A (zh) | 炎症的治疗和预防 | |
Minxuan et al. | Fisetin attenuates high fat diet-triggered hepatic lipid accumulation: A mechanism involving liver inflammation overload associated TACE/TNF-α pathway | |
CN103951721A (zh) | 槲皮素-o-糖苷衍生物在治疗脂质代谢紊乱疾病中的应用 | |
JPH11171766A (ja) | フラバノン類含有組成物 | |
CN114903879B (zh) | 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 | |
JP6261059B2 (ja) | 有色タマネギの水抽出物を含有する生活習慣病改善剤 | |
CN111000854B (zh) | 曲札茋苷在制备治疗和/或预防非酒精性脂肪肝病产品中的应用 | |
CN106456594A (zh) | PPARγ活化剂 | |
CN102631358A (zh) | 虎杖苷在制备糖尿病肾病治疗药物中的应用 | |
CN113546070B (zh) | 低聚茋类单体化合物Isohop在制备提高动物脂肪沉积的产品中的用途 | |
TWI645855B (zh) | 牛樟芝萃取纯化物之用途 | |
CN108938615A (zh) | 苯磺酰胺基苯甲酰胺类化合物用于治疗非酒精性脂肪性肝病的用途 | |
JP6576445B2 (ja) | ファルネシル類の芳香族化合物及びその応用 | |
KR102160424B1 (ko) | 유파틸린을 유효성분으로 포함하는 비만 예방, 치료, 또는 개선용 조성물 | |
CN113521055A (zh) | 低聚茋类单体化合物VitD在制备提高动物脂肪沉积的产品中的用途 | |
CN114832005A (zh) | 毛蕊花糖苷的新用途 | |
CN111544440A (zh) | 地奥司明及组合物在制备抗肥胖的产品方面中的应用 | |
CN111773324A (zh) | 鲜石斛水提物在制备治疗代谢性疾病药物中的应用 | |
JP7330575B6 (ja) | モナスシノールの脂肪減少製品の調製における使用 | |
CN115252630B (zh) | 黄柏酮在制备预防、改善或治疗非酒精性脂肪肝的药物中的应用 | |
Liu et al. | Gynura procumbens aqueous extract alleviates nonalcoholic steatohepatitis through CFLAR-JNK pathway in vivo and in vitro | |
Lin et al. | Macular pigments produced from microalga Chlorella sp. and applied to alleviate the pathogenic process in diabetic mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |